Millar J L, McElwain T J
Antibiot Chemother (1971). 1978;23:271-82. doi: 10.1159/000401490.
A pretreatment dose of cyclophosphamide reduced lethality caused by high doses of busulphan or cyclophosphamide. In the case of cyclophosphamide given prior to busulphan, increased survival could be attributed to greater regeneration of haemopoietic stem cells in animals that received the combined dose compared with those that received busulphan alone. The mechanism by which cyclophosphamide pretreatment increased the animals' tolerance to a large dose of cyclophosphamide has not yet been elucidated. However, the urothelium in mice given the combined treatment was much less damaged than the urothelium in mice given the large dose alone, and its a known that bladder damage is a major feature of toxicity in patients given high-dose cyclophosphamide. This sparing combination exerted its expected toxicity on Lewis lung tumours, however, and so provided a useful differential effect against tumour tissue.
环磷酰胺的预处理剂量降低了高剂量白消安或环磷酰胺所致的致死率。在白消安之前给予环磷酰胺的情况下，与单独接受白消安的动物相比，接受联合剂量的动物造血干细胞再生能力增强，这可归因于生存率的提高。环磷酰胺预处理提高动物对大剂量环磷酰胺耐受性的机制尚未阐明。然而，联合治疗小鼠的尿路上皮损伤程度远低于单独给予大剂量环磷酰胺小鼠的尿路上皮损伤程度，并且已知膀胱损伤是接受高剂量环磷酰胺治疗患者毒性的主要特征。然而，这种保护性联合用药对Lewis肺癌发挥了预期的毒性作用，因此对肿瘤组织产生了有益的差异效应。
